Tag: PR Newswire

LAFAYETTE, Ind., May 7, 2026 /PRNewswire/ — The article outlines mood swings, sleep disturbances, hot flashes, and treatment options including natural bioidentical hormone replacement.

Are mood changes and sleep problems in women in their 40s and 50s signs of hormone imbalance? A HelloNation article provides the answer, featuring insights from Dr. Charles Turner of Innovative Medicine in Lafayette, IN.

The HelloNation article explains that hormone imbalance is common among women in their 40s and 50s as they approach menopause. Fluctuating estrogen and progesterone levels can affect mood, sleep, weight, and overall energy. Recognizing these symptoms early allows for proper evaluation and timely treatment.

Mood swings are often one of the first noticeable changes. Women in their 40s and 50s may experience irritability, anxiety, or sudden emotional shifts without clear external causes. The article notes that hormone imbalance can influence brain chemicals linked to emotional regulation, making mood swings more frequent during menopause.

Sleep disturbances are another common concern. Difficulty falling asleep, waking during the night, or early morning awakenings can become persistent. Hot flashes and night sweats often worsen sleep disturbances, leaving many women in their 40s and 50s feeling fatigued during the day.

Hot flashes and night sweats are hallmark symptoms associated with menopause. These sudden waves of heat and perspiration can interrupt work, social activities, and rest. The article explains that while hot flashes and night sweats are normal during this transition, they may signal underlying hormone imbalance that can be managed effectively.

A thorough medical evaluation is recommended to confirm the cause of symptoms. This process may include reviewing medical history, conducting physical exams, and ordering lab work to assess hormone levels. Identifying hormone imbalance accurately ensures that treatment addresses the true source of discomfort rather than masking symptoms.

Natural bioidentical hormone replacement is presented as a treatment option for many women in their 40s and 50s experiencing menopause related symptoms. This therapy aims to restore hormonal balance in a way that aligns closely with the body’s natural chemistry. When guided by medical supervision, natural bioidentical hormone replacement may help reduce mood swings, hot flashes, and night sweats.

Weight changes and low energy are also discussed. Hormone imbalance can influence metabolism and fat distribution, often leading to increased abdominal weight. Addressing these changes through medical evaluation and natural bioidentical hormone replacement can support improved vitality and overall well being.

Bone and cardiovascular health may also be affected during menopause. Declining estrogen levels contribute to changes in bone density and cholesterol levels. The article notes that early recognition of hormone imbalance provides opportunities for preventive care and long term health planning.

Lifestyle adjustments complement medical treatment. Regular exercise, balanced nutrition, and stress management can help reduce sleep disturbances and support hormonal stability. Combining healthy habits with natural bioidentical hormone replacement often enhances results and improves quality of life.

The HelloNation article concludes that hormone imbalance in women in their 40s and 50s is common but manageable. By recognizing mood swings, sleep disturbances, hot flashes, and night sweats as possible signs of menopause, women can seek timely evaluation and explore natural bioidentical hormone replacement to restore balance and support lasting health.

Signs of Hormone Imbalance in Women in Their 40s & 50s features insights from Dr. Charles Turner, Wellness Expert of Lafayette, IN, in HelloNation.

About HelloNation
HelloNation is a premier media platform that connects readers with trusted professionals and businesses across various industries. Through its innovative “edvertising” approach that blends educational content and storytelling, HelloNation delivers expert-driven articles that inform, inspire, and empower. Covering topics from home improvement and health to business strategy and lifestyle, HelloNation highlights leaders making a meaningful impact in their communities.

View original content to download multimedia:https://www.prnewswire.com/news-releases/hellonation-examines-hormone-imbalance-signs-for-women-in-their-40s-and-50s-featuring-wellness-expert-dr-charles-turner-302766209.html

SOURCE HelloNation

NEW ORLEANS, May 7, 2026 /PRNewswire/ — Scott Vicknair Personal Injury Lawyers is proud to announce its Spring NIL class, continuing the firm’s commitment to supporting and investing in local student athletes across Louisiana.

The Spring class includes a talented group of athletes representing universities across the state: Sophia Macias of Tulane Golf, Percy Daniels of Tulane Basketball, Jordan Matthews of Nicholls Basketball, and Mackenzie Glynn of Nicholls Beach Volleyball and Track and Field.

Through Name, Image, and Likeness partnerships, the firm can directly support student athletes as they balance academics, athletics, and personal development. These partnerships reflect a broader mission to give back to the local community and uplift young leaders who represent the future of Louisiana.

“We are incredibly excited about this group of student athletes,” said David Vicknair, founding partner of the firm. “Each of them represents dedication, discipline, and the kind of work ethic we admire. Supporting them through NIL opportunities is one way we can give back and invest in the next generation.”

The firm has continued to expand its NIL efforts, focusing on partnerships with athletes who have strong ties to the Louisiana community. By working with local universities like Tulane and Nicholls, Scott Vicknair Personal Injury Lawyers aims to create meaningful opportunities that extend beyond financial support.

“These athletes are leaders both on and off the field,” said Vicknair. “We are proud to be part of their journey and look forward to seeing all they accomplish.”

Scott Vicknair Personal Injury Lawyers remains committed to building relationships within the community and supporting initiatives that create lasting impact throughout Louisiana.

About Scott Vicknair Personal Injury Lawyers

Scott Vicknair Personal Injury Lawyers is a New Orleans-based personal injury firm committed to providing exceptional legal representation while also investing in the communities it serves. Their experienced team of dedicated attorneys specializes in car accidents, personal injury, and wrongful death cases in New Orleans. With diverse personal and professional backgrounds, they craft legal-winning strategies tailored to each client’s specific case and needs. They are committed to providing exceptional legal services, utilizing significant resources, and relentlessly advocating for their clients to achieve the best possible outcomes.

View original content:https://www.prnewswire.com/news-releases/scott-vicknair-personal-injury-lawyers-announces-new-spring-nil-class-supporting-local-student-athletes-302765876.html

SOURCE Scott Vicknair Personal Injury Lawyers

NEW ORLEANS, May 7, 2026 /PRNewswire/ — Scott Vicknair Personal Injury Lawyers is proud to announce its Spring NIL class, continuing the firm’s commitment to supporting and investing in local student athletes across Louisiana.

The Spring class includes a talented group of athletes representing universities across the state: Sophia Macias of Tulane Golf, Percy Daniels of Tulane Basketball, Jordan Matthews of Nicholls Basketball, and Mackenzie Glynn of Nicholls Beach Volleyball and Track and Field.

Through Name, Image, and Likeness partnerships, the firm can directly support student athletes as they balance academics, athletics, and personal development. These partnerships reflect a broader mission to give back to the local community and uplift young leaders who represent the future of Louisiana.

“We are incredibly excited about this group of student athletes,” said David Vicknair, founding partner of the firm. “Each of them represents dedication, discipline, and the kind of work ethic we admire. Supporting them through NIL opportunities is one way we can give back and invest in the next generation.”

The firm has continued to expand its NIL efforts, focusing on partnerships with athletes who have strong ties to the Louisiana community. By working with local universities like Tulane and Nicholls, Scott Vicknair Personal Injury Lawyers aims to create meaningful opportunities that extend beyond financial support.

“These athletes are leaders both on and off the field,” said Vicknair. “We are proud to be part of their journey and look forward to seeing all they accomplish.”

Scott Vicknair Personal Injury Lawyers remains committed to building relationships within the community and supporting initiatives that create lasting impact throughout Louisiana.

About Scott Vicknair Personal Injury Lawyers

Scott Vicknair Personal Injury Lawyers is a New Orleans-based personal injury firm committed to providing exceptional legal representation while also investing in the communities it serves. Their experienced team of dedicated attorneys specializes in car accidents, personal injury, and wrongful death cases in New Orleans. With diverse personal and professional backgrounds, they craft legal-winning strategies tailored to each client’s specific case and needs. They are committed to providing exceptional legal services, utilizing significant resources, and relentlessly advocating for their clients to achieve the best possible outcomes.

View original content:https://www.prnewswire.com/news-releases/scott-vicknair-personal-injury-lawyers-announces-new-spring-nil-class-supporting-local-student-athletes-302765876.html

SOURCE Scott Vicknair Personal Injury Lawyers

CapsCanada has unified its operations under a single brand to enhance its global footprint. This strategic move maintains all existing product quality, manufacturing standards and supply chain.

DANIA BEACH, Fla., May 7, 2026 /PRNewswire/ — CapsCanada, a manufacturer of empty hard capsules and oral dosage-form solutions with more than four decades of expertise serving the pharmaceutical and nutraceutical industries, today announced its transition to a new corporate name and identity: Lyfe Group. This milestone unifies the company’s North and South Americas operations under a single, cohesive brand structure, strengthening its position in the global empty capsule and drug delivery market.

The new identity is not the result of an acquisition or merger; it is a strategic step that consolidates the company’s operations under one brand. The new name will strengthen its market position, improve clarity across regions, and support long-term scalability as the business and product portfolio continues to grow.

The launch of Lyfe Group signals a new chapter for an organization that has consistently invested in manufacturing, compliance, technical service, and supply chain reliability. In recent years, the company expanded its flagship K-CAPS® HPMC vegetarian capsule manufacturing in Windsor, Ontario; relocated its distribution headquarters to a 130,000 square-foot state-of-the-art facility in Dania Beach, Florida; launched an extensive digital technical library for customers and added innovative capsule products to its portfolio: K-CAPS® Natural Colorant Capsules and K-CAPS® Delayed Release Capsules.

“Becoming Lyfe Group is the natural next step in our journey. For more than 40 years, CapsCanada’s reliability and reputation has been built on quality products, a reliable supply chain, excellent technical service, and the depth of our customer relationships. This transition brings all of that together under a unified identity that reflects the full scope of who we are today and the ambition of where we are going. We are proud of our legacy as CapsCanada, and we are excited to write the next chapter as Lyfe Group.”

-Jonathan Gilinski, Executive Director, Lyfe Group.

The Lyfe Group® brand will roll out progressively throughout 2026. 

About Lyfe Group

Lyfe Group® (formerly CapsCanada®) is a global leader in the development and manufacture of high-quality two-piece empty capsules and advanced drug delivery solutions for the pharmaceutical, nutraceutical, and dietary supplement industries. Backed by over 40 years of manufacturing expertise and a three-generation family legacy, the company offers a comprehensive portfolio of gelatin and non-gelatin capsule technologies designed to meet evolving formulation and regulatory requirements. Lyfe Group is recognized for its unwavering commitment to quality, regulatory excellence, and technical service, supporting customers at every stage, from development through global commercialization.

Learn more at: www.lyfegroup.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/capscanada-transitions-to-lyfe-group-establishing-a-unified-corporate-identity-302765771.html

SOURCE Lyfe Group

Seven UWorld-supported Goldwater Scholars will receive financial support and product scholarships

DALLAS, May 7, 2026 /PRNewswire/ — UWorld, a global leader in comprehensive academic and professional education, has awarded more than $85,000 in financial and product scholarships for the 2026-27 academic year to 93 recipients pursuing medical research careers in fields ranging from pain pharmacology to neurodegenerative disorders. 

Through its philanthropic arm, UWorld Cares, UWorld has partnered with The Barry Goldwater Scholarship and Excellence in Education Foundation for the third consecutive year to help students pursuing medical research careers excel in the classroom and in their careers. UWorld’s donation builds on prior support for one of the nation’s most established undergraduate scholarships and continues its investment in students pursuing research careers in science, technology, engineering and mathematics (STEM). Since the 2024-25 academic year, UWorld has provided nearly $250,000 in resources and supported 255 scholars.

All Doctor of Medicine (M.D.)/Ph.D. and Doctor of Osteopathic Medicine (D.O.)/Ph.D. scholarship recipients will receive complimentary access to UWorld Grad School’s MCAT^® premier question bank. Seven UWorld-supported Goldwater Scholars will also receive a complimentary upgrade to the MCAT Comprehensive Prep Course, 90-day access to UWorld Medical’s USMLE^® Step 1 question bank and up to $7,500 in financial support. Goldwater Scholars are selected for their demonstrated research potential and commitment to careers in science and medicine.  

The UWorld-supported scholars, who all plan to pursue an M.D./Ph.D., are:

• Phoenix Bryant, a junior at the University of Maryland, Baltimore County (UMBC), in Baltimore, Maryland, who plans to study epigenetic mechanisms of mental disorders. Her research focuses on protein function in chromatin and on serotonin’s role in brain development. She has conducted research at UMBC and the Icahn School of Medicine at Mount Sinai. She serves in the student government and is a STEM editor for the UMBC Review.

• Amir Etemadi, a junior at Carleton College in Northfield, Minnesota, who plans to study hearing loss. His research includes developing a mouse model for a genetic disorder and studying mitochondrial function in auditory cells. He has performed laboratory techniques, including RNA analysis and quantitative polymerase chain reaction. He is a varsity cross-country athlete and participates in multiple student organizations.

• Hannah Henson, a junior at Mississippi State University in Starkville, Mississippi, who plans to study women’s health conditions. Her research examines immune responses in cancer treatment, including T-cell dynamics following immunotherapy and radiation. She designed and conducted the study and analyzed the results. She is a pre-health ambassador and works as a teaching assistant and instruction leader.

• Victoria Ho, a junior chemistry major at the University of Toledo in Toledo, Ohio, who plans to study pain pharmacology. Her research examines alternatives to opioids through compound synthesis in green chemistry. She has worked on multiple stages of the project, including substrate development and optimization. She is the vice president of the university’s Humanity First student chapter and helps develop a career-readiness curriculum.

• Trent Lewis, a sophomore at East Tennessee State University in Johnson City, Tennessee, who plans to study bioengineering. His research focuses on plant stress response pathways and enzyme regulation. He has presented his work at the International Genetically Engineered Machine competition in Paris. He is active in debate, student leadership and a campus scientific society.

• Cole Meador, a junior at Western Kentucky University in Bowling Green, Kentucky, who plans to study neurology. His research examines spinal cord regeneration using computational analysis of gene expression. He is interested in improving the diagnosis and treatment of atypical Parkinsonian disorders. He works at a crisis hotline and participates in community service efforts.

• Brandon Than, a junior at the University of Houston in Houston, Texas, who plans to study cancer immunology. His research at UT MD Anderson Cancer Center examines methods to enhance T-cell responses against tumors. He has contributed to a study on expanding tumor-specific immune cells. He founded a summer internship program and leads a social-emotional learning initiative for children from asylum-seeking families.

“Supporting Goldwater Scholars reflects our commitment to strengthening the pipeline of future physician-scientists and researchers,” said Chandra S. Pemmasani, M.D., founder and CEO of UWorld. “These students are already contributing to critical areas of medical research, and by investing in their training early, we can help accelerate the discoveries that will shape the future of healthcare.”

UWorld’s MCAT question bank features 3,000+ questions with detailed answer explanations plus an adaptive study planner and digital flashcards. The MCAT Comprehensive Prep Course features eight interactive print and digital MCAT prep books, 3,000+ questions with detailed answer explanations, 450 concept check questions across lessons, 1,100+ high-yield video lessons, seven Association of American Medical Colleges (AAMC^®) practice exams, and a full-length practice exam.

The USMLE Step 1 question bank offers 3,600+ exam-like questions based on real-life clinical scenarios, one self-assessment, and access to the medical library with 1,200+ expert-curated articles. 

“Investments from UWorld help ensure that talented students have the resources they need to continue their work and contribute to the nation’s research enterprise,” said John Yopp, chair of the Goldwater Board of Trustees. “These scholars are well-positioned to drive the next generation of breakthroughs in science and medicine.”

About UWorld
UWorld is a global leader in comprehensive academic and professional education. Since 2001, the company has helped more than 5 million high school, undergraduate, graduate and professional students prepare for high-stakes accounting, college admissions, finance, legal, medical, nursing and pharmacy exams and achieve their academic and career goals. UWorld supports students and educators with comprehensive courses, high-quality practice questions, and detailed answer explanations designed to improve outcomes. Aspen Publishing, Efficient Learning, JD-Next^®, Roger CPA Review^®, RxPrep^®, Surgent Accounting & Financial Education and Themis Bar Review^® are UWorld companies. Learn more at UWorld.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/uworld-supports-93-future-medical-researchers-in-partnership-with-goldwater-foundation-302765035.html

SOURCE UWorld, LLC

• Eligible Medicare patients living with obesity will have access to Wegovy^® (semaglutide) injection and pill for a $50 monthly copay
• Wegovy^® offers adults living with obesity significant weight loss, along with diet and exercise, and is FDA-approved to lower the risk of major CV events such as death, heart attack, or stroke in adults living with obesity with known heart disease, a claim only Wegovy^® can make
• Novo Nordisk’s participation in the Medicare GLP-1 Bridge expands patient access to authentic, FDA-approved Wegovy^®

PLAINSBORO, N.J., May 7, 2026 /PRNewswire/ — The Medicare GLP-1 Bridge will provide eligible Medicare beneficiaries living with obesity access to Wegovy^® (semaglutide) injection and tablets for a $50 monthly copay^†, beginning July 1, 2026, per yesterday’s announcement from the Centers for Medicare & Medicaid Services (CMS). The program represents a meaningful milestone in making FDA-approved Wegovy^® accessible for millions of America’s Medicare patients living with obesity, who can now work with their healthcare professional to start and stay on proven, FDA-approved treatment.

“Obesity is a serious, common chronic disease facing older Americans, and Wegovy^® is the only weight management medicine proven to reduce the risk of heart attack, stroke, or cardiovascular death in patients who also have known heart disease. That distinction matters for seniors age 65 and older, who have a high burden of both conditions,” said Jamey Millar, executive vice president, US Operations of Novo Nordisk. “We welcome the Medicare GLP-1 Bridge as an important step in getting Wegovy^® to more patients and will continue to work with CMS, healthcare professionals, pharmacists, and patient advocates to support implementation and help eligible seniors access the care they need and deserve.”

The Medicare GLP-1 Bridge provides eligible patients access to Wegovy^® for weight management. The Medicare GLP-1 Bridge will be available nationwide across all states and territories, providing eligible patients access to all doses and formulations of Wegovy^® injection and Wegovy^® pill, and will run through the end of 2027. It is important to note that Wegovy^® will be available for eligible Medicare beneficiaries for the other FDA-approved indications through their normal Part D benefits, including to reduce the risk of major adverse cardiovascular events in adults with established CV disease with either obesity or overweight.

Novo Nordisk is actively working with CMS, healthcare professionals, pharmacists, and patient advocacy organizations to streamline implementation, raise awareness among eligible beneficiaries, and help ensure patients can access the medicines they need. Additional program details are available at CMS.gov.

Expanding affordable access to medicines is a priority for Novo Nordisk, and the Medicare GLP-1 Bridge builds on a sustained effort to ensure patients can access authentic, FDA-approved Wegovy^®. Patients seeking information on affordability options, with or without insurance, are encouraged to visit NovoCare.com.

^†Terms apply. For eligible Medicare patients prescribed Wegovy^® for a covered FDA-approved indication. Eligibility criteria will be determined by CMS. This information is not a guarantee of coverage. Month defined as 1 box of 4 pens of Wegovy^® and 1 bottle of 30 tablets of Wegovy^®.

About obesity
Obesity is a serious, chronic, progressive, and complex disease that requires long-term management.^1-3 One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people living with obesity from losing weight and keeping it off.^1,3 Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment.^4,5

About Novo Nordisk
Novo Nordisk is a leading global healthcare company that’s been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs approximately 10,000 people throughout the country across more than 10 manufacturing, R&D and corporate locations in seven states plus Washington DC. For more information, visit novonordisk-us.com, Facebook, Instagram, and X.

What is Wegovy^®?
Wegovy^® (semaglutide) injection is a prescription medicine used with a reduced-calorie diet and increased physical activity to:

• reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight.
• help adults and children aged 12 years and older with obesity, or some adults with excess weight (overweight) who also have weight-related medical problems to lose weight and keep the weight off.

Wegovy^® (semaglutide) tablets are a prescription medicine used with a reduced-calorie diet and increased physical activity to:

• reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight.
• help adults with obesity, or some adults with excess weight (overweight) who also have weight related medical problems to lose weight and keep the weight off.

Wegovy^® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.

It is not known if Wegovy^® injection is safe and effective:

• to reduce the risk of major cardiovascular events (death, heart attack, or stroke) in people under 18 years
• to help children under 12 years of age lose weight and keep the weight off.

It is not known if Wegovy^® tablets are safe and effective for use in people under 18 years of age.

Important Safety Information

What is the most important information I should know about Wegovy^®?

Wegovy^® may cause serious side effects, including:

• Possible thyroid tumors, including cancer. Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rodents, Wegovy^® and other medicines that work like Wegovy^® caused thyroid tumors, including thyroid cancer. It is not known if Wegovy^® will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people
• Do not use Wegovy^® if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Do not use Wegovy^® if:

• you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• you have had a serious allergic reaction to semaglutide or any of the ingredients in Wegovy^® injection or Wegovy^® tablets. See symptoms of serious allergic reaction in “What are the possible side effects of Wegovy^®?”

Before using Wegovy^®, tell your healthcare provider if you have any other medical conditions, including if you:

• have or have had problems with your pancreas or kidneys
• have type 2 diabetes and a history of diabetic retinopathy
• are scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)
• are pregnant or plan to become pregnant. Wegovy^® may harm your unborn baby. You should stop using Wegovy^® 2 months before you plan to become pregnant
• are breastfeeding or plan to breastfeed. Breastfeeding is not recommended during treatment with Wegovy^® tablets. It is not known if Wegovy^® when received through an injection passes into your breast milk

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Wegovy^® may affect the way some medicines work and some medicines may affect the way Wegovy^® works. Tell your healthcare provider if you are taking other medicines to treat diabetes, including sulfonylureas or insulin. Wegovy^® slows stomach emptying and can affect medicines that need to pass through the stomach quickly.

What are the possible side effects of Wegovy^®?
Wegovy^® may cause serious side effects, including:

• inflammation of your pancreas (pancreatitis). Stop using Wegovy® and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back
• gallbladder problems. Wegovy^® may cause gallbladder problems, including gallstones. Some gallstones may need surgery. Call your healthcare provider if you have symptoms, such as pain in your upper stomach (abdomen), fever, yellowing of the skin or eyes (jaundice), or clay-colored stools
• increased risk of low blood sugar (hypoglycemia), especially those who also take medicines for diabetes such as insulin or sulfonylureas. This can be a serious side effect. Talk to your healthcare provider about how to recognize and treat low blood sugar and check your blood sugar before you start and while you take Wegovy®. Signs and symptoms of low blood sugar may include dizziness or light-headedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or drowsiness, shakiness, weakness, headache, fast heartbeat, or feeling jittery
• dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away
• severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Wegovy^®. Tell your healthcare provider if you have stomach problems that are severe or will not go away
• serious allergic reactions. Stop using Wegovy^® and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat
• change in vision in people with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Wegovy^®
• increased heart rate. Wegovy^® can increase your heart rate while you are at rest. Tell your healthcare provider if you feel your heart racing or pounding in your chest and it lasts for several minutes
• food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Wegovy^® may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Wegovy^® before you are scheduled to have surgery or other procedures

The most common side effects of Wegovy^® may include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, changes in skin sensations, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and hair loss.

Please click here for Prescribing Information including Boxed Warning and Medication Guide for Wegovy^®.

Contacts for further information

References:

1. Kaplan LM, Golden A, Jinnett K, et al. Perceptions of barriers to effective obesity care: results from the national action study. Obesity. 2018;26(1):61–69.
2. Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017;18(7):715–723.
3. Garvey WT, Mechanick JI, Brett EM, et al. American association of clinical endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22 (Suppl 3):1–203.
4. Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide 25 mg in adults with overweight or obesity. N Engl J Med. 2025; 393:1077-1087. DOI: 10.1056/NEJMoa2500969.
5. Centers for Disease Control and Prevention. Risk Factors for Obesity. Last accessed: December 2025. Available at: https://www.cdc.gov/obesity/risk-factors/risk-factors.html

View original content to download multimedia:https://www.prnewswire.com/news-releases/wegovy-access-expanded-for-medicare-beneficiaries-living-with-obesity-through-the-medicare-glp-1-bridge-starting-july-1-2026-302764949.html

SOURCE Novo Nordisk

BOSTON, May 7, 2026 /PRNewswire/ — VOTF, a Catholic Lay Apostolate committed to promoting transparency in Church operations, has published its 2025 diocesan financial transparency report. Before being released publicly, the reports were sent to each diocesan bishop and to CFOs of each of the 176 geographical dioceses in the USCCB. The average overall 2025 transparency score dropped 6 points from 71% to 66%. In 2025, the number of dioceses posting current audited financial reports of their central operations decreased from 114 to 112 (64%). The all-time high for posting current audited reports was 116 dioceses in 2023. More details for the 2025 results may be found here.

The downward trend in reporting observed in 2025 is due primarily to dioceses failing to post the information in a timely fashion. Our hope is that dioceses will make progress toward more consistent financial reporting going forward. Despite lower scores the overall financial transparency picture is still positive, with many dioceses demonstrating dedication to transparency and accountability. Five dioceses scored 100%, while only six scored 20% or lower. The Archdiocese of Kansas City in Kansas and the Dioceses of Lexington KY, Nashville TN, Rochester NY and Youngstown OH received perfect transparency scores in 2025. The Archdiocese of New York once again received the lowest transparency score in the USCCB at 12%.

Four other New York dioceses are going through bankruptcy proceedings as a way of dealing with large claims of clerical child sexual abuse, but the Archdiocese has thus far avoided the financial disclosure that accompanies bankruptcy by selling land holdings in New York City to raise $300 million dollars for abuse settlements. New York received a score of 37% in 2021, 2022 and 2023 but dropped to 12% in 2024 as the financial problems facing the Archdiocese mounted. Sharing more financial information, not less, will help to regain needed trust and support from members of the Archdiocese. We are hopeful that New York will rebound from its position as the lowest scorer in the U.S. under new diocesan leadership and provide an exampleof financial transparency and accountability to the other members of the USCCB.

VOTF congratulates those dioceses that led the way in transparency and accountability in 2025 and those that made significant gains this year as well. We remain committed to working for transparency throughout the Church. Such transparency can enhance lay stewardship, promote generosity, and build trust in the leadership of the Catholic Church nationwide.

Voice of the Faithful News Release, April 27, 2026, Margaret Roylance, mroylance@votf.org, (781) 559-3360

Voice of the Faithful^®: Voice of the Faithful’s^® mission is to provide a prayerful voice, attentive to the Spirit, through which the Faithful can actively participate in the governance and guidance of the Catholic Church. VOTF’s goals are to support survivors of clergy sexual abuse, to support priests of integrity, and to shape structural change within the Catholic Church. More information is at www.votf.org.

View original content to download multimedia:https://www.prnewswire.com/news-releases/voice-of-the-faithful-votf-releases-results-of-the-2025-diocesan-financial-transparency-review-302765016.html

SOURCE Voice of the Faithful

KUNSHAN, China, May 7, 2026 /PRNewswire/ — Arctech, a world-leading solar tracking and smart energy solution provider, held a launch ceremony for its ArcTrack Mobile Solar-Tracking & Storage Microgrid Solution in Jakarta.

By innovatively integrating solar, storage, intelligence, and control into one system, ArcTrack delivers a reliable, efficient, and cost-effective energy solution for every off-grid and temporary power scenario ­- providing stable and safe power for all scenarios, enabling fast and efficient installation and O&M, and optimizing lifecycle cost-benefit while improving end-to-end carbon efficiency.

Specifically, it provides stable power in extreme conditions from -30°C to 60°C, while withstanding force‑10 winds, and can be installed by two people in just one day with plug‑and‑play operation, supporting up to six parallel units. The system optimizes lifecycle costs by delivering 20% lower transport, 50% less site prep, 40% higher asset utilization, and over 400% ROI, while reducing the levelized cost of electricity by up to 90%. Each unit can cut CO₂ emissions by 32.4 tons annually.

At the ceremony, Arctech Chairman Mr. Cai reaffirmed the company’s commitment to localizing manufacturing and services, while a strategic partnership with PT Pilar was announced to strengthen regional value chains.

Over the following three days at SolarTech Indonesia Exhibition, the spotlight remained on ArcTrack. Live demos of the mobile microgrid drew strong interest from engineers and EPC partners, highlighting its plug‑and‑play deployment and off‑grid economics.

Alongside ArcTrack, Arctech also showcased its SkyLine II tracker (adapting to 30° slopes) and SkyFlex large-span cable mounting system (15–60m spans), further demonstrating the company’s ability to address Indonesia’s hilly terrain and dispersed project sites.

The solutions demonstrated Arctech’s deepened commitment to Indonesia’s ambitious energy transition, addressing the country’s unique archipelagic terrain, grid gaps, and complex installation conditions. As the leading tracker provider in the Asia-Pacific region for consecutive years, Arctech is doubling down on its local team, technical support, and end-to-end service capabilities – with the same commitment extending across Southeast Asia.

Moving forward, Arctech will continue to drive customer-centric innovation, deepening its participation from project investment and business model creation to customized smart energy development. Together with local partners, the company is committed to building a resilient green grid across Indonesia and beyond.

Learn more about Arctech: https://en.arctechsolar.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/arctech-launched-arctrack-mobile-solar-tracking–storage-microgrid-solution-at-solartech-indonesia-2026-powering-indonesias-green-transition-302765432.html

SOURCE Arctech Solar

NINGDE, China, May 7, 2026 /PRNewswire/ — On April 29^th, Contemporary Amperex Intelligent Technology (Shanghai) Limited (CAIT), CATL’s skateboard chassis arm, has entered into a strategic partnership with Turkish automotive brand Togg to jointly develop chassis platform for its new B-segment vehicle family, marking the first overseas passenger vehicle project for the platform.

Under the agreement, CAIT will contribute its Bedrock Chassis technology and engineering expertise, while working closely with Togg to co-develop the platform for three models in Togg’s new B-segment vehicle family. Developed in line with Togg’s product strategy, user expectations and mobility ecosystem, the platform will support next-generation electric vehicles for the Turkish and European markets, with Togg playing a defining role in shaping the user experience, product requirements and digital architecture. The first model developed under the partnership is expected to enter mass production in 2027.

Battery-centric chassis architecture

The Bedrock Chassis is an integrated intelligent chassis built around a “battery-centric” architecture. It combines core chassis components including the battery, electric drive system, thermal management system and chassis domain controller into a single platform. This integration allows the chassis to manage both vehicle energy and motion control, effectively acting as a mobile energy carrier for the vehicle.

Robin Zeng, Chairman and CEO of CATL, said, “This collaboration represents another important milestone in the global expansion of the CATL Bedrock Chassis following its mass production rollout in the Chinese market. It will also serve as a benchmark project in the field of integrated intelligent chassis, strengthening our global partnerships, accelerating electrification and supporting the transition to low-carbon mobility in emerging new energy markets.”

Commenting on the partnership, Togg Chairman Fuat Tosyalı said: “We see mobility not merely as a product category, but as a holistic matter of technology and ecosystem. In this direction, we are taking the partnerships we establish beyond conventional supplier relationships and turning them into strategic partnerships that create shared value and build the future together. Rather than adopting a ready-made solution, we are becoming part of the entire development process, responding more effectively to user needs while also contributing to the development of this ecosystem in our country. In the period ahead, through such value-creating partnerships, we will further enrich the Togg ecosystem and the experience we offer our users by developing new solutions across different segments.”

Localised model for global markets

The Bedrock Chassis has been developed for global deployment through a “1+1+1” localisation model. This model combines one chassis technology platform with one industrial supply chain pathway and the localised operation of one domestic automotive brand. The aim is to allow electric vehicles to be designed and produced in ways that reflect the needs of local markets while using a common technological foundation.

The partnership with Togg is expected to apply this approach in Türkiye, supporting the development of vehicles tailored to regional consumer preferences while strengthening the local electric vehicle ecosystem.

Expanding international partnerships

In 2024, the Bedrock Chassis achieved mass production in the Chinese market, marking the world’s first deployment of an integrated intelligent chassis offered as a standalone product to passenger vehicle brands.

CAIT is continuing to expand cooperation around the Bedrock Chassis in several regions, including Europe and Southeast Asia. The platform is designed to help emerging automotive markets build competitive electric vehicle industries more efficiently, while supporting the global shift towards low-emission mobility.

View original content to download multimedia:https://www.prnewswire.com/news-releases/catl-subsidiary-cait-partners-up-with-togg-on-bedrock-chassis-302765410.html

SOURCE Contemporary Amperex Intelligent Technology (Shanghai) Limited (CAIT)

SHANGHAI, May 7, 2026 /PRNewswire/ — Pylontech (688063.SH), a leading global energy storage system provider, has been recognized as a BloombergNEF (BNEF) Tier 1 Energy Storage Manufacturer for Q2 2026, underscoring the company’s bankability, proven project execution capabilities, and established position in the global energy storage market.

The BNEF Tier 1 list is regarded as one of the industry’s most rigorous evaluation benchmarks for energy storage companies. The assessment considers factors including technological capabilities, product reliability, large-scale project execution track record, and financial credibility. Pylontech’s inclusion in the Tier 1 list reflects its growing global project portfolio and long-standing commitment to delivering reliable energy storage solutions across a wide range of applications and markets. Recent utility-scale projects delivered by Pylontech include the Ningxia Yinchuan 200MW/400MWh Energy Storage Project and the Jiangsu Huadian Yizheng 120MW/240MWh Energy Storage Power Station in China.

“BNEF Tier 1 recognition reflects the market’s confidence in Pylontech’s technology, product quality, and long-term reliability,” said a spokesperson for Pylontech. “This recognition further reinforces Pylontech’s position as a trusted partner for utility-scale and commercial energy storage projects worldwide.”

With more than a decade of expertise in energy storage innovation, Pylontech has established a vertically integrated platform spanning battery cells, modules, battery management systems (BMS), and system integration. The company continues to expand its global presence while supporting the transition toward a cleaner, more resilient, and sustainable energy future.

About Pylontech

Founded in 2009, Pylontech (688063.SH) is a dedicated energy storage system provider that went public on the STAR Market in 2020, becoming the first listed company in China focused on energy storage as its core business. With extensive expertise in electrochemistry, power electronics, and system integration, Pylontech has delivered reliable energy storage products and solutions to the global market, establishing itself as a leading player in the industry. Its products are widely used in various scenarios, including solutions for residential, C&I, grid-side storage, communication base station and data center energy storage, light-duty electric vehicles, battery-swapping and more. Website: https://en.pylontech.com.cn/?lan=en

View original content to download multimedia:https://www.prnewswire.com/news-releases/pylontech-recognized-as-bloombergnef-tier-1-energy-storage-manufacturer-302765354.html

SOURCE Pylontech